Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

0333598 - ÚMG 2011 RIV DE eng J - Journal Article
Šímová, Jana - Indrová, Marie - Bieblová, Jana - Mikyšková, Romana - Bubeník, Jan - Reiniš, Milan
Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
International Journal of Cancer. Roč. 126, č. 12 (2010), s. 2997-3004. ISSN 0020-7136. E-ISSN 1097-0215
R&D Projects: GA ČR GA301/06/0774; GA AV ČR IAA500520807; GA ČR GA301/07/1410; GA ČR GA301/09/1024
EU Projects: European Commission(XE) 18933 - CLINIGENE
Institutional research plan: CEZ:AV0Z50520514
Keywords : beta-galactosylceramide * tumour immunotherapy * NKT cells
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 4.926, year: 2010

Permanent Link: http://hdl.handle.net/11104/0178543